I can tell you that VDPHL01 has a unique profile unlike current FDA-approved treatments, which are associated with cardiac ...

Ward Carson didn’t think twice when asked by his doctor to participate in a clinical trial for a treatment for prostate cancer. The 82-year-old retired chartered accountant was diagnosed in 2003 with ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Some oncologists suggest that, for certain early cancers not at risk of spreading, the term “cancer” should be avoided.

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

Prostate cancer is one of the most prevalent cancers among men and poses a significant health concern, with its incidence on the rise. In Thailand, it is the 4th most common cancer among men (1), ...

The treatment has become increasingly popular, especially among older men. Here is what to keep in mind if you are ...

There seems to be no association between hormone therapy (HT) and glioma risk among US women, according to a study published online.

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help doctors make better decisions ...

Felix Y. Feng, MD Under his guidance, biologists and computational scientists in the Feng Laboratory at UCSF produced the first clinical-grade biomarker panels that predict prostate cancer response to ...

were unsuitable to receive more hormonal therapy, and had already received one or two rounds of chemotherapy for advanced or metastatic cancer. Patients were randomly assigned to receive either ...